http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108047333-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 |
| filingDate | 2018-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108047333-B |
| titleOfInvention | Specific antibody with CD33 as target, CAR-NK cell, and preparation and application thereof |
| abstract | The present invention provides an anti-CD33 antibody or antigen-binding fragment thereof, wherein the antibody comprises a heavy chain variable region (VH) and/or a light chain variable region (VL), wherein the heavy chain variable region comprises a heavy chain VHCDR1, VHCDR2, VHCDR 3; the light chain variable region comprises a light chain VLCDR1, VLCDR2, VLCDR 3. The invention provides an antibody or an antigen binding fragment thereof with CD33 as a target spot, and the CD33CAR-NK cell constructed by the antibody is obtained by culturing and amplifying a monoclonal cell strain, has stable properties, and can be used for large-scale production and preparation. The CD33CAR-NK cell takes a CD33 molecule as a target antigen, can specifically kill or kill myeloid leukemia cells, can be used as a therapeutic drug for myeloid leukemia diseases, and is used for treating the myeloid leukemia with high expression of a CD33 molecule. |
| priorityDate | 2018-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 328.